Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Inogen target raised to $83 at Needham — HME adoption of POCs drove strong results again in 4Q16 (68.62)Needham raises their INGN tgt to $83 from $78 after co beat consensus rev, EBITDA, and EPS in 4Q16 and mgmt raised its 2017 rev, EBITDA, and EPS guidance. The rev upside was driven by 56% growth in B2B more than offsetting 3% growth in DTC. We note that the 21st Century Cures Act resulted in $2M of additional revenue as Medicare reimbursement cuts were retroactively reversed. Additionally, INGN adopted ASU 2016-09 which reduced its 2016 income tax by $6M (increasing its 2016 EPS by $0.29). <strong>Firm still views guidance as conservative and expects INGN's rev growth to increase as the G4 becomes more widely available across its sales channels and as it laps the Medicare reimbursement cuts; Strong Buy.</strong></td> </tr></table>"